1Department of Pharmacy, Comilla University
10Assistant Professor, Department of Pharmacy, Comilla University, Bangladesh
2Associate Professor, Cardiology Himalayan Institute of Medical Science, Jolly GrantDehradun248140UttaranchalIndia
3Australian Computer Society
4Professor, Department of Biochemistry, Symbiosis Medical College for Women, Symbiosis International (Deemed University), Pune
5Universidad Nacional "San Luis Gonzaga" - Peru
6National University of Huancavelica, Huancavelica - Peru
7Industrial Technology Development Institute, Department of Science and Technology, Taguig City, Philippines
8Human Performance and Health, Aristotle University of Thessaloniki, Thesaaloniki, Macedonia, Greece
9Department of Pharmaceutical Chemistry, College of Pharmacy, University of Ahl Al Bayt, 56001, Karbala, Iraq
*Corresponding Author E-mail: rezwanmahed747@gmail.com
Online Published on 2 November, 2023.
Nipah virus (NIV) infection was identified in 1998, in Malaysia. The virus belongs to the Paramyxoviridae family. In the past, the virus was spread in Bangladesh, India, as well as Singapore. It affects our nervous system and the respiratory system, which is highly dangerous for our lives. It is caused by an RNA virus and has a high mortality rate. This virus can be transmitted from bats to humans, pigs to humans, or humans to humans. It is conceptualized that fruit bats like Pteropus vampyrus and Pteropus hypomelanus are responsible for transmitting the virus. From 1999 to 2022, there is no approved vaccine and medicines for the treatment of nipah virus infection. The fatality rate of this nipah virus is 75% to 95%. Moreover, NiV B (Bangladesh) is more deathly than NiV M (Malaysia). In present, some vaccines are under trial on pigs, horses and the monkey. In this review we try to focus on the barrier of vaccine and medicine development for this nipah virus.
Nipah virus (NIV), Encephalitis, Respiratory system, Pathogenicity, Molecular Epidemiology, Bats, Bangladesh, Etc
